FDA finalizes cell and gene therapy potency guidance
Published . Updated .
In a final guidance issued on Monday, the US Food and Drug Administration (FDA) laid out its expectations for cell and gene therapy (CGT) sponsors to demonstrate that their products meet potency standards through the developer a potency assurance strategy.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- MRK Merck+4.0% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.95% | -0.31% | base | after close | after close | after close | after close |
| XBI | +1.84% | +3.78% | base | after close | after close | after close | after close |
| LLY | -9.22% | -2.71% | base | after close | after close | after close | after close |
| JNJ | -0.68% | +1.70% | base | after close | after close | after close | after close |
| PFE | -3.00% | -2.47% | base | after close | after close | after close | after close |
| MRK | -4.45% | -1.43% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
FDA finalizes cell and gene therapy potency guidance RAPS
Source: RAPS
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | +1.70% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.68% | final price |
| Eli Lilly (LLY) | three days earlier | -2.71% | final price |
| Eli Lilly (LLY) | five days earlier | -9.22% | final price |
| Merck (MRK) | three days earlier | -1.43% | final price |
| Merck (MRK) | five days earlier | -4.45% | final price |
| Pfizer (PFE) | three days earlier | -2.47% | final price |
| Pfizer (PFE) | five days earlier | -3.00% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.78% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.84% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.31% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 55 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 73 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 75 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies carried with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “FDA finalizes cell and gene therapy potency guidance.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- XBI Spdr Series Trust
In “FDA finalizes cell and gene therapy potency guidance,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- LLY Eli Lilly
In “FDA finalizes cell and gene therapy potency guidance,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- JNJ Johnson & Johnson
In “FDA finalizes cell and gene therapy potency guidance,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- PFE Pfizer
In “FDA finalizes cell and gene therapy potency guidance,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- MRK Merck
For “FDA finalizes cell and gene therapy potency guidance,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
How “FDA finalizes cell and gene therapy potency guidance” reaches Select Sector Spdr Tr (XLV)
On 2 Nov 2026, “FDA finalizes cell and gene therapy potency guidance” is the story that connects Select Sector Spdr Tr (XLV) to this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Dates in the story, and the Select Sector Spdr Tr (XLV) price range
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1415.62.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“FDA finalizes cell and gene therapy potency guidance” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.